Peptide profile
GLP-1 (7-36) Amide
Endogenous GLP-1 for meal-time satiety
Compare GLP-1 (7-36) Amide with other peptides →Summary
A natural body peptide that helps control hunger right away.
- Typical dose
- 50-200mcg Before each meal (3x daily)
- Route
- Subcutaneous
- Cycle length
- As needed
- Evidence
- Animal data
Mechanism
How it works
Native GLP-1 works like a meal-time dimmer switch for hunger — you inject it right before eating to briefly turn down appetite and slow stomach emptying.
GLP-1 (7-36) amide is the biologically active form of endogenous glucagon-like peptide-1 with a half-life of less than 2 minutes, rapidly metabolized by DPP-4 enzymes.
Reported in research
Benefits
- Lowers your hunger fast before you eat
- Slows down how quickly your stomach empties for a little while
- Helps your body make insulin when your blood sugar is up
- Goes away very fast (2-3 minutes)
Context, not a prescription
Dosing
- Typical range
- 50-200mcg Before each meal (3x daily) (Subcutaneous)
- Cycle length
- As needed
Safety
Side effects & contraindications
Possible side effects
- Nausea (short-lived)
- Injection site pain
- Severe vomiting
- Hypoglycemia
Contraindications
- Pregnancy or breastfeeding
- Insulinoma
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
You eat smaller meals, feel full longer, and have lower blood sugar after eating.
How it works
Natural GLP-1 works like a dimmer switch for hunger at meals. You take the shot right before eating. It briefly turns down your appetite and slows your stomach.
It turns on switches in your pancreas to make insulin. It slows your stomach. It tells your brain you feel full.
What to expect
Starts in 15-30 minutes and lasts about 60-90 minutes.
- 15-30 min after the shot: Hunger is lowered the most.
- 60-90 min: The effects start to fade.
- Meal days: You eat less food at each meal.
Good to know
- Take the shot right before you eat
- Start small with 50mcg
- Do not use if your blood sugar is low
Staying safe
- Feeling sick to your stomach (only for a short time)
- Pain where you got the shot
Avoid if you have:
- Pregnant moms or moms who are breastfeeding
- People with a tumor that makes too much insulin
Mechanism of action
GLP-1 (7-36) amide is the biologically active form of endogenous glucagon-like peptide-1 with a half-life of less than 2 minutes, rapidly metabolized by DPP-4 enzymes.
Activates GLP-1 receptors on pancreatic beta cells (insulin secretion), gastric smooth muscle (delayed emptying), and hypothalamic satiety centers.
Pharmacodynamics
Within 15-30 minutes, lasts ~60-90 minutes.
Reduced meal size, prolonged fullness, lower post-prandial glucose.
Timeline
- 15-30 min post-inject: Peak appetite suppression.
- 60-90 min: Effects wearing off.
- Meal days: Reduced calorie intake per meal.
Comparisons
- GLP-1 (7-36) — effectiveness Moderate, safety Emerging, cost $$, Hard to use
- Semaglutide — effectiveness Very High, safety Good, cost $$$, Easy to use
Adverse effects
Common:
- Nausea (short-lived)
- Injection site pain
Rare:
- Severe vomiting
- Hypoglycemia
Contraindications & risk mitigation
Contraindicated in:
- Pregnancy or breastfeeding
- Insulinoma
- Inject immediately before meals
- Start with 50mcg
- Do not use if blood sugar is low
Qué hace
Comes porciones más pequeñas, te sientes lleno por más tiempo y tienes menos azúcar en sangre después de comer.
Cómo funciona
El GLP-1 natural funciona como un regulador de intensidad para el hambre en las comidas. Te aplicas la inyección justo antes de comer. Reduce brevemente tu apetito y ralentiza el estómago.
Activa interruptores en tu páncreas para producir insulina. Ralentiza tu estómago. Le indica a tu cerebro que te sientes lleno.
Qué esperar
Comienza en 15-30 minutos y dura aproximadamente 60-90 minutos.
- 15-30 min después de la inyección: El hambre se reduce al máximo.
- 60-90 min: Los efectos comienzan a desvanecerse.
- Días de comidas: Comes menos cantidad en cada comida.
Bueno saber
- Aplicar la inyección justo antes de comer
- Comenzar con una dosis baja de 50 mcg
- No usar si tu azúcar en sangre está bajo
Manteniéndose seguro
- Sentirse con náuseas (solo por un breve periodo)
- Dolor en el lugar de la inyección
Evitar si tienes:
- Mujeres embarazadas o en periodo de lactancia
- Personas con un tumor que produce demasiada insulina
Mecanismo de acción
La amida GLP-1 (7-36) es la forma biológicamente activa del péptido similar al glucagón endógeno, con una vida media inferior a 2 minutos, metabolizada rápidamente por las enzimas DPP-4.
Activa los receptores GLP-1 en las células beta pancreáticas (secreción de insulina), el músculo liso gástrico (vaciado retardado) y los centros de saciedad hipotalámicos.
Farmacodinamia
En 15-30 minutos, dura aproximadamente 60-90 minutos.
Reducción del tamaño de las comidas, saciedad prolongada, menor glucosa posprandial.
Cronología
- 15-30 min post-inyección: Supresión máxima del apetito.
- 60-90 min: Los efectos comienzan a disminuir.
- Días de comidas: Menor ingesta calórica por comida.
Comparaciones
- GLP-1 (7-36) — efectividad Moderada, seguridad Emergente, costo $$, Difícil de usar
- Semaglutida — efectividad Muy Alta, seguridad Buena, costo $$$, Fácil de usar
Efectos adversos
Comunes:
- Náuseas (de corta duración)
- Dolor en el sitio de inyección
Raros:
- Vómitos severos
- Hipoglucemia
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Embarazo o lactancia
- Insulinoma
- Inyectar inmediatamente antes de las comidas
- Comenzar con 50 mcg
- No usar si el azúcar en sangre está bajo
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- As needed
FAQ
Common questions
Why use native GLP-1 instead of semaglutide?
For acute, on-demand appetite control rather than continuous suppression.
Can it be taken orally?
No, DPP-4 degrades it within minutes; injection required.
What is the evidence level?
This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Research
Research & sources
Current evidence for GLP-1 (7-36) Amide is rated as Animal data. Research is based primarily on animal models.
- 1. GLP-1 physiology (2012) — DOI:10.1152/physrev.00034.2011
- 2. Short-acting GLP-1 agonists (2019) — DOI:10.2337/dc19-0045
- 3. GLP-1 physiology (2012)
- 4. Short-acting GLP-1 agonists (2019)